Key Highlights MRNA stock climbed 3.37% in pre-market hours following nationwide FDA authorization of mFLUSIVA. FDA granted authorization for mFLUSIVA targeting all adults 50 years and above
Shares of Moderna advanced in pre-market trading Thursday following federal regulatory clearance for its messenger RNA-based influenza vaccine designed for older American adults. The stock climbed 3.37% to reach $58.15 before market open, rebounding from Wednesday’s 1.29% decline that closed at $56.26. This authorization expands Moderna’s commercial vaccine lineup and strengthens its presence in the U.S. respiratory disease prevention market.
The FDA authorized mFLUSIVA for administration to adults who have reached 50 years of age or older throughout the nation. This regulatory green light came after receiving unanimous backing from the agency’s Vaccines and Related Biological Products Advisory Committee. With this latest authorization, Moderna’s portfolio now includes four approved products in its domestic market.
The vaccine leverages Moderna’s messenger RNA technology platform to combat seasonal influenza virus strains. This creates an additional preventive tool for mature adults who experience elevated risks from influenza-related complications. Commercial availability is slated to begin during the upcoming 2026-2027 respiratory disease season.
Moderna will distribute mFLUSIVA alongside its existing products Spikevax, mRESVIA, and mNEXSPIKE for qualified patient groups. This product suite addresses influenza, respiratory syncytial virus, and COVID-19 prevention needs. The expanded offering enhances Moderna’s competitive standing in annual vaccination campaigns.
The pivotal Phase 3 clinical study recruited 40,805 adults aged 50 and above from 11 different nations. Scientists evaluated mFLUSIVA against a conventional-dose influenza vaccine by tracking laboratory-verified influenza cases. The research protocol also assessed safety parameters, adverse reactions, and comparative vaccine performance.
The FDA issued standard authorization for individuals between 50 and 64 years of age. This determination stemmed from efficacy and safety evidence gathered during the multinational clinical investigation. Moderna documented a favorable safety record with no unexpected concerns emerging throughout the Phase 3 research program.
For adults 65 years and older, the FDA provided accelerated authorization through an alternative clinical framework. A supplementary trial included 2,992 U.S.-based participants. Scientists evaluated immune system responses compared against a high-dosage inactivated influenza vaccine formulation.
Moderna faces requirements to verify clinical advantages for the 65-and-older age group via a post-authorization confirmatory study. The biotechnology firm will maintain ongoing safety surveillance following commercial distribution across the country. These obligations constitute standard elements of the FDA’s accelerated authorization framework.
Health authorities across the European Union, Canada, and Australia are actively evaluating mRNA-1010. Moderna intends to file additional regulatory applications in other markets throughout 2026. Broader international authorizations would significantly increase the vaccine’s global commercial opportunity beyond American borders.
This FDA authorization delivers another revenue-generating product as Moderna works to decrease dependency on COVID-19 vaccine revenues. Seasonal influenza represents a substantial recurring market with consistent demand among older demographics each respiratory illness season. The pre-market stock advance reflected investor optimism following the approval news and enhanced near-term trading sentiment.
The post Moderna (MRNA) Stock Climbs After FDA Greenlights First mRNA Flu Vaccine mFLUSIVA appeared first on Blockonomi.
